USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Cardiovalve Ltd.

USPTO PatentsView assignee record - 119 granted patents across 16 technology areas, recorded in grant years 2018–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).

RSS updates for this company

The verdict

According to USPTO PatentsView, Cardiovalve ranks #3,153 of 49,997 tracked US assignees by granted-patent volume, with 119 patents across 16 technology areas.

#3,153
of 49,997 US assignees by volume
Top 14%
by Innovation Score (50.0/100)
21.4
avg claims per patent
+395%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R3153 · Foreign Corporation #3,153 · 119 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-MID 119 grants
  • TOP-DECILE #3,153/49,997
  • PHOTO-FINISH Adva Optical…
  • CPC-FOCUS A61F · 16 areas
  • INNOV-PAR 50.0/100
  • CLAIMS-DENSE 21.4 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-SURGE +395% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Adva Optical Networking SE (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Cardiovalve

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Cardiovalve's Innovation Score is 50.0/100 (top 14% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Cardiovalve's grants concentrate

Cardiovalve Ltd. is a focused PatentsView assignee: 16 CPC subclasses with 98.3% of grants classified under A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device). Peak complete grant year is 2020 (25 grants) versus a trough of 2 in 2018. By volume, Cardiovalve sits between Adva Optical Networking SE and Icom Incorporated.

Cardiovalve's three-year grant acceleration

From 2019–2021 to 2022–2024, Cardiovalve Ltd. moved from 56 to 55 grants (0.98x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #1,229. See the growth leaderboard.

Who files at Cardiovalve's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Cardiovalve holds 119 patents at rank #3,153, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Cardiovalve

By rank, the assignees closest to #3,153 in granted patent volume.

Leaders in A61F (Filters Implantable Into Blood Vessels)

Other assignees with the most granted patents in Cardiovalve's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Cardiovalve, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (50 here).

Similar claim depth

Nearest assignees by average claims per patent (21.4 here).

Cardiovalve's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

50 Top 14% higher than 86% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0102030 20182019202020212022202320242025 6
USPTO utility patent grants by year · 2018–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table
Cardiovalve Ltd. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2018 2 1.7%
2019 17 14.3%
2020 25 21.0%
2021 14 11.8%
2022 22 18.5%
2023 15 12.6%
2024 18 15.1%
2025partial year 6 5.0%

Which technologies does Cardiovalve Ltd. patent most?

Top 15 of 16 technology areas

Where it ranks

Overall rank by patents

#3,153

of 49,997 tracked assignees

Innovation Score

50.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Cardiovalve Ltd.'s patent record in context - here's where to go next.

  • Cardiovalve Ltd.'s lead technology class is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device), 98.3% of its portfolio - see every assignee active in that class. Explore A61F
  • Ranked #3,153 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Cardiovalve Ltd. against Adva Optical Networking SE, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 50.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.